Loading patent…
AssigneeGlycoEra AG
InventorsGanesh Venkataraman Kaundinya, Tanmoy Chinmoy Ganguly, Rainer Follador, Manuela Mally, Jonathan Albert Back, Michela Manni, Dominique Nicolas Sirena
Estimating the term…
Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to an anti-neutrophil autoantibody and a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites. Also provided herein are nucleic acid sequence encoding provided glycoengineered polypeptides. Further provided herein are compositions comprising glycoengineered polypeptides and/or nucleic acids encoding the same, as well as methods of making and using the same.
A glycoengineered polypeptide comprising:
The glycoengineered polypeptide of any one of the preceding claims, wherein the glycoengineered polypeptide is capable of binding to:
The glycoengineered polypeptide of any one of the preceding claims, wherein the second moiety specifically binds to one or more endocytic receptors.
The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans comprises a terminal GlcNac, a terminal GalNac, or a terminal Gal.
The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans is an N-glycan, optionally wherein the N-glycan is linked to the first moiety of the glycoengineered polypeptide at 1, 2, 3, 4 or 5 N-glycosylation sites.
The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans comprises a glycan structure comprising GlcNAc2-Man3-GlcNAc2, GalNAc2-GlcNAc2-Man3-GlcNAc2, Gal2-GlcNAc2-Man3-GlcNAc2, GlcNAc1-Man3-GlcNAc2, Gal2-GlcNAc2-Man3-GlcNAc2, Gal1-GlcNAc2-Man3-GlcNAc2, GalNAc1-GlcNAc2-Man3-GlcNAc2, GlcNAc3-Man3-GlcNAc2, GlcNAc4-Man3-GlcNAc2, Gal3-GlcNAc3-Man3-GlcNAc2, GalNAc3-GlcNAc3-Man3-GlcNAc2, GalNAc4-GlcNAc4-Man3-GlcNAc2, Gal4-GlcNAc4-Man3-GlcNAc2, or Man-6-P—N-glycan.
The glycoengineered polypeptide of any one of the preceding claims, wherein the glycoengineered polypeptide comprises a first moiety comprising one or more peptides that specifically binds to an anti-PR3 autoantibody or a fragment thereof.
The glycoengineered polypeptide of any one of the preceding claims, wherein the first moiety comprises (i) one or more anti-PR3 autoantibody binding polypeptides and (ii) one or more anti-MPO autoantibody binding polypeptides.
The glycoengineered polypeptide of any one of the preceding claims, wherein the polypeptide comprises one or more additional elements chosen from:
The glycoengineered polypeptide of any one of the preceding claims, wherein the second moiety is conjugated to the first moiety in vivo.
A polynucleotide encoding the glycoengineered polypeptide of any one of the preceding claims.
The method of 56 or 57, wherein the ANCA vasculitis is Granulomatosis with Polyangiitis (GPA)/cytoplasmic ANCA (Formerly called Wegener's Granulomatosis).
Dependencies are inferred from the claim text.